Document is current

Article History

Received: 3 March 2025

Accepted: 5 May 2025

First Online: 3 July 2025

Declarations

:

: Francesco Paneni and Era Gorica manage the collection “Cardiometabolic HFpEF with focus on type 2 diabetes mellitus” and the co-author Francesco Paneni is also an Associate Editor of the journal. They haven't been involved in the peer review of this article. Prof. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years (remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich/University of Zurich) reports research-, educational- and/or travel grants from Abbott, Abiomed, Alnylam, Amarin, Amgen, Astra Zeneca, At the Limits Ltd., Bayer, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, CM Microport, Concept Medical, CTI, Daiichi Sankyo, Davos Congress, Edwards Lifesciences, FomF GmbH, Hamilton Health Sciences, Holcim, IHF, Innosuisse, IumiraDX, Kantar, LabPoint, MedAlliance, Medcon International, Medical Education Global Solutions, Medtronic, MicroPort, Monocle, Novartis, Novo Nordisk, OM Pharma, Pfizer, Quintiles Switzerland Sarl, RecorMedical, Roche Diagnostics, Roche Pharma, Sahajanand IN, Sanofi, Sarstedt AG, Servier, Sorin SRM SAS, SSS Int., Terumo Deutschland, Trama Solutions, V- Wave, Vifor, ZOLL. These grants do not impact on Prof. Ruschitzka`s personal remuneration. AJF declares fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Roche, Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca and Berlin Heart unrelated to this article. DN disclosures honoraria, consultant fees and/or travel expenses from Abbott, Amgen, Astra Zeneca, Bristol Myers Squibb SA, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dr. Willmar Schwabe GmbH & Co. KG, Emilwood Service Limited, Gerson Lehman Group (GLG) Consulting, Novartis, Novo Nordisk, Pfizer, walk and feel, and Zoll. FP reports receiving fees for serving on advisory boards from Novo Nordisk.